Lexeo Therapeutics (LXEO) Liabilities and Shareholders Equity (2022 - 2026)

Lexeo Therapeutics has reported Liabilities and Shareholders Equity for 5 years, with the latest figure at $250.4 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 99.19% year-over-year to $250.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $839.0 million (up 31.39% YoY) and the FY2025 annual result came in at $268.7 million, up 82.85% from the prior year.
• Liabilities and Shareholders Equity slipped to $250.4 million in Q1 2026 per LXEO's latest filing, from $268.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $268.7 million in Q4 2025 and troughed at $54.7 million in Q3 2023.
• A 5-year average of $165.2 million and a median of $160.4 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity jumped 217.71% in 2024, then slumped 41.05% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $97.1 million in 2022, then jumped by 44.02% to $139.8 million in 2023, then rose by 5.1% to $146.9 million in 2024, then jumped by 82.85% to $268.7 million in 2025, then decreased by 6.82% to $250.4 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $250.4 million, $268.7 million, and $143.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.